Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

r of 2011.  
  • On March 22, Auxilium announced that it has granted Asahi Kasei Pharma exclusive rights to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan. Asahi Kasei Pharma will be primarily responsible for the clinical development, regulatory and commercialization activities for XIAFLEX in Japan.  The Company received a $15 million up-front payment from Asahi Kasei Pharma in the first quarter of 2011.
  • The Company exceeded the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.  In excess of 800 patients have been enrolled in the two double-blind placebo-controlled phase III trials.  Top-line data is expected in the second quarter of 2012.
  • Beginning January 1, a new XIAFLEX-specific J-code (J0775) was available for use in the U.S. to identify XIAFLEX for obtaining reimbursement from Medicare, Medicaid and commercial health plans.
  • On April 11, the Company announced that it will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc. (Pfizer), following the first sale of XIAPEX in the United Kingdom.  Auxilium is eligible to receive up to $30 million in additional regulatory milestone payments for this indication, which will be paid in $7.5 million increments, following Pfizer's first sale of XIAPEX in each of the remaining major markets of the EU.  

  • Testim:

  • Worldwide revenues for Testim were $46.1 million, up 4% over the first quarter of 2010.
  • According to IMS Health, Inc., a pharmaceutical market research firm ("IMS"), over 172,000 total prescriptions for Testim were dispensed in the first quarter of 2011, a growth of 9% over the first quarter of 2010.
  • Total Testim units reported by IMS on a prescription basis exceeded total Testim units sold to customers during the first quarter of 2011, as wholesalers reduced their d
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
    3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
    4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
    (Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
    (Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
    (Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
    Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
    ... NEW YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a ... positive data from its ICH compliant Phase II ... from allergic,rhinitis. MRX-4 was given as an intranasal ... study was conducted in allergic,rhinitis patients outside of ...
    ... world leadership in the ... ingredients, - New S2383 flavor enhancer may be used in beverages, ... healthcare products to reduce the need for sucralose, ... (Nasdaq: SNMX ), a leading company,focused on using proprietary technologies ...
    ... NOVATO, Calif., Nov. 6 BioMarin,Pharmaceutical Inc. (Nasdaq: ... clinical,studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R),(galsulfase) and enzyme ... disease will be presented at the 58th Annual ... in Philadelphia,Pennsylvania, November 11-15, 2008., "We look ...
    Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 2Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 3
    (Date:10/1/2014)... rainforests, prairies and forests of the world can also ... according to a surprising new study led by Colorado ... , The research team analyzed 596 soil samples collected ... stunning diversity of below-ground life, most of which had ... to 16.2 percent of the organisms discovered in the ...
    (Date:9/30/2014)... is published today in the first authoritative scientific study ... on both sides of the grouse moor management debate. ... the Ecohydrology of River basins) project has shown that ... support red grouse populations for gun sports, has significant ... properties, river water chemistry and river ecology. , A ...
    (Date:9/30/2014)... as something that we enjoy when we visit a national ... think of ourselves as a part of nature? A bird,s ... house? , The answers to these questions reflect different ... speech and in cultural artifacts. , A new Northwestern University ... Indian Center of Chicago and the Menominee tribe of Wisconsin, ...
    Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2
    ... . , Halle/Saale. Invasive plant species can flourish ... origin. The reasons for this can be genetic changes or ... to adapt to the newcomers. These are the conclusions of ... their research on Buddleia or the Butterfly bush (Buddleja davidii) ...
    ... Stanford researchers have joined the ranks of investigators for ... 14 current HHMI investigators at Stanford, 11 of which ... HHMI investigators nationwide. Stanford,s recipients are: , ... applied physics. His research group is seeking to understand ...
    ... linked to lung disease may have a 70-percent to ... report in the May 26 issue of Archives of ... disorder, alpha1-antitrypsin deficiency (1ATD), is one of the most ... those of European descent, according to background information in ...
    Cached Biology News:When the butterfly bush blossoms 2When the butterfly bush blossoms 34 Stanford faculty named Howard Hughes Medical Institute Investigators 2Genetic mutation associated with increased risk of lung cancer 2
    ... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
    Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
    CHIMAERIC HUMAN IgA2 ANTI NP...
    ... Zero Background/Kan Cloning Kit includes ... resistance for selection in E. ... positive selection to eliminate high ... of the reagents you need ...
    Biology Products: